Table 4.

Adverse Events Related to Treatment

Adverse events	Sorafenib-based (n=35)			HAIC-based (n=38)
	All grades	Grade 3&4		All grades	Grade 3&4
Hematologic
Neutropenia	1 (2.9)	1 (2.9)		9 (23.7)	4 (10.5)
Anemia	7 (20.0)	1 (2.9)		14 (36.8)	3 (7.9)
Thrombocytopenia	3 (8.6)	0		17 (44.7)	8 (21.1)
Dermatologic
Hand-foot skin reaction	10 (28.6)	3 (8.6)		0	0
Rash	1 (2.9)	0		0	0
Scrotal erythema	1 (2.9)	0		0	0
Gastrointestinal
Dyspepsia/anorexia	9 (25.7)	2 (5.7)		5 (13.2)	1 (2.6)
Nausea/vomiting	7 (20.0)	3 (8.6)		4 (10.5)	0
Diarrhea/constipation	6 (17.1)	2 (5.7)		2 (5.3)	1 (2.6)
Abdominal pain	3 (8.6)	1 (2.9)		2 (5.3)	0
GI bleeding	2 (5.7)	1 (2.9)		1 (2.6)	1 (2.6)
HCC rupture	2 (5.7)	2 (5.7)		1 (2.6)	1 (2.6)
Constitutional
Fatigue	10 (28.6)	5 (14.3)		3 (7.9)	0
General weakness	2 (5.7)	0		3 (7.9)	2 (5.3)
Laboratory
AST elevation	8 (22.9)	8 (22.9)		6 (15.8)	5 (13.2)
ALT elevation	2 (5.7)	1 (2.9)		5 (13.2)	3 (7.9)
Bilirubin elevation	13 (37.1)	6 (17.1)		6 (15.8)	0
PT INR elevation	12 (34.3)	0		6 (15.8)	0
Hyponatremia	1 (2.9)	1 (2.9)		0	0
Complication of liver cirrhosis
Ascites aggravation	2 (5.7)	2 (5.7)		0	0
SBP	1 (2.9)	1 (2.9)		2 (5.3)	2 (5.3)
Hepatic encephalopathy	2 (5.7)	2 (5.7)		1 (2.6)	1 (2.6)
Catheter related complication
Catheter obstruction	0	0		2 (5.3)	1 (2.6)
Chemoport site infection	0	0		4 (10.5)	3 (7.9)
Hepatic artery total occlusion	0	0		1 (2.6)	1 (2.6)
Others
Infection	0	0		4 (10.5)	4 (10.5)
Febrile neutropenia	0	0		1 (2.6)	1 (2.6)
Peripheral neuropathy	1 (2.9)	0		1 (2.6)	0
Dizziness	2 (5.7)	0		1 (2.6)	0

Data are presented as number (%).

HAIC, hepatic arterial infusion chemotherapy; GI, gastrointestinal; HCC, hepatocellular carcinoma; AST, aspartate aminotransferase; ALT, alanine aminotransferase; PT, prothrombin time; INR, international normalized ratio; SBP, spontaneous bacterial peritonitis.